National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Guselkumab (Tremfya®) for psoriatic arthritis. HTA ID 20059

Guselkumab (Tremfya®)  is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/12/2020
Rapid review completed 17/02/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that guselkumab not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.